Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Ingredion has entered a major new chapter with its recommended all-cash offer to acquire Tate & Lyle, a transaction valuing the U.K.-based ingredients specialist at an enterprise value of roughly £3.7 billion, or about $5 billion.</li><li>The move follows Ingredion’s multi-year push to shift its portfolio away from traditional ingredients and toward higher-value specialty solutions focused on texture, sugar reduction, nutrition, and formulation support.</li><li>Tate & Lyle brings around $2.7 billion in fiscal 2026 revenue, about $570 million in adjusted EBITDA, nearly 5,000 employees, and a patent portfolio of roughly 1,000.</li></ul>

Ingredion has entered a major new chapter with its recommended all-cash offer to acquire Tate & Lyle, a transaction valuing the U.K.-based ingredients specialist at an enterprise value of roughly £3.7 billion, or about $5 billion.The move follows Ingredion’s multi-year push to shift its portfolio away from traditional ingredients and toward higher-value specialty solutions focused on texture, sugar reduction, nutrition, and formulation support.Tate & Lyle brings around $2.7 billion in fiscal 2026 revenue, about $570 million in adjusted EBITDA, nearly 5,000 employees, and a patent portfolio of roughly 1,000.

Ingredion’s $5 Billion Tate & Lyle Takeover Could Be A Specialty Ingredients Shift!

Ingredion Inc

Ingredion’s $5 Billion Tate & Lyle Takeover Could Be A Specialty Ingredients Shift!